The Journal of Experimental Medicine
PBL InterferonSource
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
Published online April 9, 2007
doi:10.1084/jem.20062024
The Journal of Experimental Medicine, Vol. 204, No. 4, 747-758
The Rockefeller University Press, 0022-1007 $30.00
© 2007 Waisman et al.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow PPT slides of all figures
Right arrow Supplemental Material Index
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Waisman, A.
Right arrow Articles by Rajewsky, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Waisman, A.
Right arrow Articles by Rajewsky, K.
Related Collections
Right arrowRelated Article
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

ARTICLE

 IgG1 B cell receptor signaling is inhibited by CD22 and promotes the development of B cells whose survival is less dependent on Ig{alpha}/ß

Ari Waisman1, Manfred Kraus1,4,5, Jane Seagal4,5, Snigdha Ghosh6, Doron Melamed4,5,7, Jian Song1,2,3, Yoshiteru Sasaki4,5, Sabine Classen1, Claudia Lutz8, Frank Brombacher9, Lars Nitschke6, and Klaus Rajewsky1,4,5

1 Institute for Genetics and 2 Center for Molecular Medicine, University of Cologne, 50674 Cologne, Germany
3 I. Medical Department, Johannes Gutenberg-University Mainz, 55131 Mainz, Germany
4 CBR Institute for Biomedical Research and 5 Department of Pathology, Harvard Medical School, Boston, MA 02115
6 Department of Genetics, University of Erlangen, 91058 Erlangen, Germany
7 Department of Immunology, Ruth and Bruce Rappaport Faculty of Medicine and Rappaport Family Institute for Research in the Medical Sciences, Technion-Israel Institute of Technology, Haifa 31096, Israel
8 Max-Planck-Institute of Immunobiology, 79011 Freiburg, Germany
9 Department of Immunology, Groote Schuur Hospital, University of Cape Town, Cape Town 7925, South Africa

CORRESPONDENCE Klaus Rajewsky rajewsky{at}cbr.med.harvard.edu OR Ari Waisman: waisman{at}uni-mainz.de

We describe a mouse strain in which B cell development relies either on the expression of membrane-bound immunoglobulin (Ig) {gamma}1 or µ heavy chains. Progenitor cells expressing {gamma}1 chains from the beginning generate a peripheral B cell compartment of normal size with all subsets, but a partial block is seen at the pro– to pre–B cell transition. Accordingly, {gamma}1-driven B cell development is disfavored in competition with developing B cells expressing a wild-type (WT) IgH locus. However, the mutant B cells display a long half-life and accumulate in the mature B cell compartment, and even though partial truncation of the Ig{alpha} cytoplasmic tail compromises their development, it does not affect their maintenance, as it does in WT cells. IgG1-expressing B cells showed an enhanced Ca2+ response upon B cell receptor cross-linking, which was not due to a lack of inhibition by CD22. The enhanced Ca2+ response was also observed in mature B cells that had been switched from IgM to IgG1 expression in vivo. Collectively, these results suggest that the {gamma}1 chain can exert a unique signaling function that can partially replace that of the Ig{alpha}/ß heterodimer in B cell maintenance and may contribute to memory B cell physiology.

Abbreviations used: BAFF, B cell–activating factor; BCR, B cell receptor; C, constant region; CFSE, carboxyfluorescein succinimidyl ester; ERK, extracellular signal–related kinase; ES, embryonic stem; H, heavy; HRP, horseradish peroxidase; JNK, c-Jun N-terminal kinase; MZ, marginal zone; pBCR, pre-BCR; SHP-1, Src homology domain 2–containing protein tyrosine phosphatase; TLR, Toll-like receptor.

A. Waisman, M. Kraus, J. Seagal, L. Nitschke, and K. Rajewsky contributed equally to this work.

M. Kraus's present address is Merck Research Laboratories, Boston, MA 02115.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article

Enhancement and suppression of signaling by the conserved tail of IgG memory–type B cell antigen receptors
Keisuke Horikawa, Stephen W. Martin, Sarah L. Pogue, Karlee Silver, Kaiman Peng, Kiyoshi Takatsu, and Christopher C. Goodnow
J. Exp. Med. 2007 204: 759-769. [Abstract] [Full Text] [PDF]



This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS